181 related articles for article (PubMed ID: 14563935)
1. The role of follistatin domains in follistatin biological action.
Keutmann HT; Schneyer AL; Sidis Y
Mol Endocrinol; 2004 Jan; 18(1):228-40. PubMed ID: 14563935
[TBL] [Abstract][Full Text] [Related]
2. Heparin and activin-binding determinants in follistatin and FSTL3.
Sidis Y; Schneyer AL; Keutmann HT
Endocrinology; 2005 Jan; 146(1):130-6. PubMed ID: 15471966
[TBL] [Abstract][Full Text] [Related]
3. Follistatin: essential role for the N-terminal domain in activin binding and neutralization.
Sidis Y; Schneyer AL; Sluss PM; Johnson LN; Keutmann HT
J Biol Chem; 2001 May; 276(21):17718-26. PubMed ID: 11279126
[TBL] [Abstract][Full Text] [Related]
4. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.
Sidis Y; Tortoriello DV; Holmes WE; Pan Y; Keutmann HT; Schneyer AL
Endocrinology; 2002 May; 143(5):1613-24. PubMed ID: 11956142
[TBL] [Abstract][Full Text] [Related]
5. Analysis of human follistatin structure: identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins.
Wang Q; Keutmann HT; Schneyer AL; Sluss PM
Endocrinology; 2000 Sep; 141(9):3183-93. PubMed ID: 10965889
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the inhibition of activin signalling by follistatin.
Harrington AE; Morris-Triggs SA; Ruotolo BT; Robinson CV; Ohnuma S; Hyvönen M
EMBO J; 2006 Mar; 25(5):1035-45. PubMed ID: 16482217
[TBL] [Abstract][Full Text] [Related]
8. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.
Stamler R; Keutmann HT; Sidis Y; Kattamuri C; Schneyer A; Thompson TB
J Biol Chem; 2008 Nov; 283(47):32831-8. PubMed ID: 18768470
[TBL] [Abstract][Full Text] [Related]
9. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.
Thompson TB; Lerch TF; Cook RW; Woodruff TK; Jardetzky TS
Dev Cell; 2005 Oct; 9(4):535-43. PubMed ID: 16198295
[TBL] [Abstract][Full Text] [Related]
10. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG).
Schneyer A; Schoen A; Quigg A; Sidis Y
Endocrinology; 2003 May; 144(5):1671-4. PubMed ID: 12697670
[TBL] [Abstract][Full Text] [Related]
11. Purification of recombinant activin A using the second follistatin domain of follistatin-related gene (FLRG).
Arai KY; Tsuchida K; Li C; Watanabe G; Sugino H; Taya K; Nishiyama T
Protein Expr Purif; 2006 Sep; 49(1):78-82. PubMed ID: 16737827
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the existence of a local activin follistatin negative feedback loop in the goldfish pituitary and its regulation by activin and gonadal steroids.
Cheng GF; Yuen CW; Ge W
J Endocrinol; 2007 Dec; 195(3):373-84. PubMed ID: 18000300
[TBL] [Abstract][Full Text] [Related]
13. Follistatin and its role as an activin-binding protein.
Sugino H; Sugino K; Hashimoto O; Shoji H; Nakamura T
J Med Invest; 1997 Aug; 44(1-2):1-14. PubMed ID: 9395712
[TBL] [Abstract][Full Text] [Related]
14. The heparin binding site of follistatin is involved in its interaction with activin.
Sumitomo S; Inouye S; Liu XJ; Ling N; Shimasaki S
Biochem Biophys Res Commun; 1995 Mar; 208(1):1-9. PubMed ID: 7887917
[TBL] [Abstract][Full Text] [Related]
15. Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin.
Glister C; Kemp CF; Knight PG
Reproduction; 2004 Feb; 127(2):239-54. PubMed ID: 15056790
[TBL] [Abstract][Full Text] [Related]
16. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.
Schneyer AL; Sidis Y; Gulati A; Sun JL; Keutmann H; Krasney PA
Endocrinology; 2008 Sep; 149(9):4589-95. PubMed ID: 18535106
[TBL] [Abstract][Full Text] [Related]
17. Site-specific mutagenesis of human follistatin.
Inouye S; Guo Y; Ling N; Shimasaki S
Biochem Biophys Res Commun; 1991 Aug; 179(1):352-8. PubMed ID: 1883364
[TBL] [Abstract][Full Text] [Related]
18. Follistatin restricts bone morphogenetic protein (BMP)-2 action on the differentiation of osteoblasts in fetal rat mandibular cells.
Abe Y; Abe T; Aida Y; Hara Y; Maeda K
J Bone Miner Res; 2004 Aug; 19(8):1302-7. PubMed ID: 15231018
[TBL] [Abstract][Full Text] [Related]
19. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state.
McConnell DS; Wang Q; Sluss PM; Bolf N; Khoury RH; Schneyer AL; Midgley AR; Reame NE; Crowley WF; Padmanabhan V
J Clin Endocrinol Metab; 1998 Mar; 83(3):851-8. PubMed ID: 9506739
[TBL] [Abstract][Full Text] [Related]
20. Activin-A regulates follistatin secretion from cultured rat anterior pituitary cells.
Bilezikjian LM; Corrigan AZ; Vaughan JM; Vale WM
Endocrinology; 1993 Dec; 133(6):2554-60. PubMed ID: 8243277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
